ADHERE-S (NIS Brilique)

August 5, 2020 updated by: AstraZeneca

Non-interventional Prospective Data Collection on Persistence and Adherence on Ticagrelor in ACS Adult Patients in Serbia

noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

269

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Serbia
      • Belgrade, Serbia
        • Clinical Center of Serbia
      • Belgrade, Serbia
        • CHC Bezanijska Kosa
      • Belgrade, Serbia
        • Medical Military Academy
      • Belgrade, Serbia
        • CHC Zemun
      • Belgrade, Serbia
        • CHC Zvezdara
      • Belgrade, Serbia
        • Institute for cardiovascular diseases, Dedinje
      • Kragujevac, Serbia
        • Clinical Center Kragujevac
      • Nis, Serbia
        • Clinical Center Nis
      • Sremska Kamenica, Serbia
        • Institute for Cardiovascular diseases of Vojvodina

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult ACS patients

Description

Inclusion Criteria:

  • ≥ 18 years of age
  • diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated
  • Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation.
  • read and signed the Informed Consent Form

Exclusion Criteria:

Any contraindications as per approved SmPC of Brilique

• Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
duration (number of days) on ticagrelor therapy in patients with acute coronary syndrome
Time Frame: 1 year (12 months)
1 year (12 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 5, 2018

Primary Completion (Actual)

August 13, 2019

Study Completion (Actual)

August 13, 2019

Study Registration Dates

First Submitted

February 9, 2018

First Submitted That Met QC Criteria

February 19, 2018

First Posted (Actual)

February 23, 2018

Study Record Updates

Last Update Posted (Actual)

August 7, 2020

Last Update Submitted That Met QC Criteria

August 5, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • D5130R00052

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ACS (Acute Coronary Syndrome)

Clinical Trials on ticagrelor 90 mg

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe